Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 16/20 | 0.38 |
| ▸ | HTR2B | P41595 | 16/20 | 0.38 |
| ▸ | HTR2A | P28223 | 15/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4415979 | 0.99 | AXL (0.40) | AXLHTR2CHTR2BHTR2APIM1 | |
| SCHEMBL13595230 | 0.83 | HTR2C (0.43) | AXLHTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL4406505 | 0.82 | HTR2C (0.42) | AXLHTR2CHTR2BHTR2A | |
| SCHEMBL13595233 | 0.81 | HTR2C (0.47) | AXLHTR2CHTR2BHTR2A | |
| SCHEMBL14480662 | 0.80 | HTR2C (0.43) | HTR2CHTR2BHTR2APIK3CB | |
| Hydrochloric Acid SCHEMBL4411296 | 0.80 | HTR2C (0.46) | AXLHTR2CHTR2BHTR2A | |
| SCHEMBL13595226 | 0.77 | AXL (0.46) | AXLHTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL4408955 | 0.76 | AXL (0.46) | AXLHTR2CHTR2BHTR2A | |
| SCHEMBL14480498 | 0.74 | HTR2C (0.43) | HTR2CHTR2BHTR2A | |
| SCHEMBL4419512 | 0.73 | USP30 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | AXL 1428/4885HTR2C 1/4885HTR2B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.